Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol 2023; 44(06): 585-591
DOI: 10.1055/s-0043-1769489
Perspective

Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms

Manali Satiza 
1   Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
,
Abhishek HL Purohit 
1   Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Introduction

Myeloproliferative neoplasms (MPNs) are defined by clonal proliferation of hematopoietic stem cells leading to uncontrolled proliferation of mature myeloid cells, which are hypersensitive to cytokine stimulation for proliferation, cell survival, and differentiation.[1] The incidence of MPNs is 2.3 to 2.8 per 100,000 persons/year and it is primarily a disease of elderly and slightly more common in males.[2] All the entities have distinguishing features based on affected cell lines and fibrosis in the bone marrow compartment.[3]

Authors' Contributions

M.S. was involved in writing–original draft and data curation. A.H.L.P. contributed to conceptualization, resources, and writing of the original draft.




Publication History

Article published online:
27 November 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 2017; 129 (06) 680-692
    CrossrefPubMedGoogle Scholar
  • 2 Iurlo A, Cattaneo D, Bucelli C, Baldini L. New perspectives on polycythemia vera: from diagnosis to therapy. Int J Mol Sci 2020; 21 (16) 5805
    CrossrefPubMedGoogle Scholar
  • 3 Dixith R, Sara A, Vangala N. et al. Clinicopathological spectrum of BCR:ABL-negative myeloproliferative neoplasms with correlation with Janus-associated kinase 2 mutation. Indian J Med Paediatr Oncol 2019; 40 (01) 35-40
    Article in Thieme ConnectGoogle Scholar
  • 4 DePalma L, Delgado P, Werner M. Diagnostic discrimination and cost-effective assay strategy for leukocyte alkaline phosphatase. Clin Chim Acta 1996; 244 (01) 83-90
    CrossrefPubMedGoogle Scholar
  • 5 Khoury JD, Solary E, Abla O. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36 (07) 1703-1719
    CrossrefPubMedGoogle Scholar
  • 6 Maddali M, Kulkarni UP, Ravindra N. et al. Mutation profile in BCR:ABL1-negative myeloproliferative neoplasms: a single-center experience from India. Hematol Oncol Stem Cell Ther 2021
    PubMedGoogle Scholar
  • 7 Rabade N, Subramanian PG, Kodgule R. et al. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India. Indian J Pathol Microbiol 2018; 61 (02) 209-213
    CrossrefPubMedGoogle Scholar
  • 8 Mughal TI, Gotlib J, Mesa R. et al. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res 2018; 67: 67-74
    CrossrefPubMedGoogle Scholar
  • 9 Polyatskin IL, Artemyeva AS, Krivolapov YA. [Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors]. Arkh Patol 2019; 81 (03) 59-65
    CrossrefPubMedGoogle Scholar
  • 10 Kim J, Byun JM, Hong J. et al. Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms. Sci Rep 2021; 11 (01) 17819
    CrossrefPubMedGoogle Scholar
  • 11 Rumi E, Boveri E, Bellini M. et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget 2017; 8 (60) 101735-101744
    CrossrefPubMedGoogle Scholar
  • 12 Arachchillage DJ, Mackillop L, Chandratheva A, Motawani J, MacCallum P, Laffan M. Guidelines for thrombophilia testing: A British Society for Haematology guideline. Br J Haematol 2022
    PubMedGoogle Scholar
  • 13 Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 2017; 129 (06) 667-679
    CrossrefPubMedGoogle Scholar
  • 14 Behnert A, Meyer J, Parsa JY. et al. Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. Leukemia 2022; 36 (01) 279-282
    CrossrefPubMedGoogle Scholar
  • 15 Wang SA, Hasserjian RP, Tam W. et al. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica 2017; 102 (08) 1352-1360
    CrossrefPubMedGoogle Scholar
  • 16 Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011; 117 (21) 5710-5718
    CrossrefPubMedGoogle Scholar
  • 17 Patnaik MM, Timm MM, Vallapureddy R. et al. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J 2017; 7 (07) e584
    CrossrefPubMedGoogle Scholar
  • 18 Marcellino B, El Jamal SM, Mascarenhas JO. Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clin Adv Hematol Oncol 2018; 16 (09) 619-626
    PubMedGoogle Scholar
  • 19 Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 2008; 87 (01) 1-10
    CrossrefPubMedGoogle Scholar
  • 20 Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2021; 96 (01) 145-162
    CrossrefPubMedGoogle Scholar
  • 21 Carobbio A, Finazzi G, Antonioli E. et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 2009; 37 (09) 1016-1021
    CrossrefPubMedGoogle Scholar
  • 22 Takahashi K, Patel KP, Kantarjian H. et al. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood 2013; 122 (23) 3784-3786
    CrossrefPubMedGoogle Scholar
  • 23 Park SH, Chi HS, Cho YU, Jang S, Park CJ. The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasm. Blood Res 2013; 48 (02) 128-132
    CrossrefPubMedGoogle Scholar